Ken Griffin’s Select Medical SEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$915K Sell
56,153
-166,032
-75% -$2.6M ﹤0.01% 7861
2025
Q4
$3.3M Sell
222,185
-135,765
-38% -$1.92M ﹤0.01% 4991
2025
Q3
$4.6M Sell
357,950
-142,833
-29% -$1.9M ﹤0.01% 4517
2025
Q2
$7.6M Buy
+500,783
New +$7.81M ﹤0.01% 3429
2025
Q1
Sell
-458,072
Closed -$8.43M 15452
2024
Q4
$8.63M Buy
+458,072
New +$8.83M ﹤0.01% 3171
2024
Q3
Sell
-209,080
Closed -$4.01M 15130
2024
Q2
$3.95M Buy
209,080
+165,293
+377% +$2.82M ﹤0.01% 4122
2024
Q1
$711K Sell
43,787
-254,968
-85% -$3.73M ﹤0.01% 7639
2023
Q4
$3.78M Sell
298,755
-23,029
-7% -$291K ﹤0.01% 4235
2023
Q3
$4.38M Buy
321,784
+27,589
+9% +$426K ﹤0.01% 3881
2023
Q2
$5.05M Sell
294,195
-433,880
-60% -$6.72M ﹤0.01% 3628
2023
Q1
$10.1M Buy
728,075
+453,235
+165% +$6.67M ﹤0.01% 2803
2022
Q4
$3.68M Sell
274,840
-13,675
-5% -$177K ﹤0.01% 4399
2022
Q3
$3.44M Sell
288,515
-41,181
-12% -$585K ﹤0.01% 4536
2022
Q2
$4.2M Sell
329,696
-272,639
-45% -$3.5M ﹤0.01% 4135
2022
Q1
$7.79M Buy
602,335
+583,192
+3,047% +$7.7M ﹤0.01% 3372
2021
Q4
$303K Buy
+19,143
New +$327K ﹤0.01% 10898
2021
Q3
Sell
-370,970
Closed -$7.36M 14557
2021
Q2
$8.45M Sell
370,970
-42,937
-10% -$891K ﹤0.01% 3380
2021
Q1
$7.61M Buy
413,907
+393,738
+1,952% +$6.46M ﹤0.01% 3426
2020
Q4
$301K Sell
20,169
-25,234
-56% -$329K ﹤0.01% 9073
2020
Q3
$509K Buy
45,403
+23,383
+106% +$230K ﹤0.01% 7272
2020
Q2
$175K Sell
22,020
-634,885
-97% -$5.26M ﹤0.01% 8626
2020
Q1
$5.31M Buy
656,905
+513,557
+358% +$6.1M ﹤0.01% 2623
2019
Q4
$1.8M Buy
143,348
+120,278
+521% +$1.3M ﹤0.01% 4580
2019
Q3
$206K Buy
23,070
+3,914
+20% +$34.2K ﹤0.01% 8112
2019
Q2
$164K Sell
19,156
-863,589
-98% -$6.82M ﹤0.01% 8316
2019
Q1
$6.7M Buy
882,745
+279,777
+46% +$2.25M ﹤0.01% 2581
2018
Q4
$4.99M Buy
602,968
+289,989
+93% +$2.77M ﹤0.01% 2793
2018
Q3
$3.1M Buy
312,979
+236,052
+307% +$2.44M ﹤0.01% 3684
2018
Q2
$752K Sell
76,927
-42,872
-36% -$421K ﹤0.01% 5707
2018
Q1
$1.11M Buy
119,799
+6,219
+5% +$59.2K ﹤0.01% 4662
2017
Q4
$1.08M Sell
113,580
-98,691
-46% -$943K ﹤0.01% 4553
2017
Q3
$2.2M Buy
212,271
+114,504
+117% +$1.06M ﹤0.01% 3300
2017
Q2
$809K Sell
97,767
-34,328
-26% -$258K ﹤0.01% 4406
2017
Q1
$950K Buy
132,095
+80,654
+157% +$585K ﹤0.01% 4077
2016
Q4
$367K Buy
+51,441
New +$358K ﹤0.01% 5380
2016
Q3
Sell
-70,654
Closed -$414K 7705
2016
Q2
$414K Sell
70,654
-385,168
-84% -$2.55M ﹤0.01% 4749
2016
Q1
$2.9M Buy
455,822
+352,693
+342% +$1.89M ﹤0.01% 2283
2015
Q4
$662K Buy
103,129
+20,628
+25% +$129K ﹤0.01% 4104
2015
Q3
$480K Buy
82,501
+72,937
+763% +$541K ﹤0.01% 4863
2015
Q2
$83K Sell
9,564
-50,932
-84% -$428K ﹤0.01% 7274
2015
Q1
$483K Buy
60,496
+2,702
+5% +$20.2K ﹤0.01% 4959
2014
Q4
$448K Buy
+57,794
New +$422K ﹤0.01% 4881
2014
Q3
Sell
-17,138
Closed -$132K 8370
2014
Q2
$144K Buy
+17,138
New +$133K ﹤0.01% 5902
2014
Q1
Sell
-518,876
Closed -$3.25M 7995
2013
Q4
$3.25M Sell
518,876
-609,102
-54% -$2.97M ﹤0.01% 2062
2013
Q3
$4.9M Sell
1,127,978
-1,098,829
-49% -$5.02M 0.01% 1605
2013
Q2
$9.84M Buy
+2,226,807
New +$9.86M 0.02% 1077

Other funds holding SEM

Ken Griffin's SEM Position: Q1 2026 in Review

Ken Griffin reduced its Select Medical (SEM) stake by 75% in Q1 2026, selling an estimated $2.6M and leaving 56,153 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #7861.

Ken Griffin first reported a position in SEM in Q2 2013 and has held it in 46 quarters since. The position peaked at $10.1M in Q1 2023. 277 funds tracked by Wall St. Rank hold SEM as of Q1 2026.

  • Ken Griffin held 56,153 shares of Select Medical worth $915K as of Q1 2026.
  • Ken Griffin sold 166,032 Select Medical shares in Q1 2026, an estimated $2.6M.
  • Select Medical made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7861 holding.
  • Ken Griffin first reported a position in Select Medical in Q2 2013 and has held it in 46 quarters since.
  • Ken Griffin's Select Medical position peaked at $10.1M in Q1 2023.
  • 277 funds tracked by Wall St. Rank held Select Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.